Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.

MSD intends to bolster its ophthalmology portfolio. Credit: Paul Diaconu from Pixabay.